Oxford BioTherapeutics has completed a number of successful investment rounds, and is supported by a syndicate of leading specialist investors. In addition to this equity funding, a significant proportion of the outgoing investment into our innovative IO and antibody-drug conjugate pipelines is generated through our strategic alliances with leading companies in the sector. Our investors include a number of specialists: